EACS2023: 153 Bikswitch study: effectiveness and safety of switching to a bictegravir-based antiretroviral therapy regimen from non-integrase inhibitor-based therapies in virologically suppressed HIV-infected patients F. Perez , F. Jover , E. Delgado , J. Peris , M.A. Bernabeu Hospital Clinico Universitario San Juan Alicante, Infectious Diseases Unit, Alicante, Spain, Hospital Clinico Universitario San Juan Alicante, Pharmacy Department, Alicante, Spain General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Bictegravir-based regimens are considered one of the first lines of antiretroviral therapy for treating naive patients in major clinical guidelines. Its safety profile, its few interactions, the fact that it has no treatment-emergent resistance described to date, and its proven virological efficacy suggest that suppressed HIV patients may benefit from the switch. To evaluate whether patients receiving other antiretroviral regimens not based on integrase inhibitors can switch to B/F/TAF without compromising safety or efficacy. Method: Descriptive and retrospective observational study of adult HIV-infected patients on effective ART who switched to a bictegravir-based regimen from regimens without INI. We compared patients' viral load, CD4+ lymphocyte concentration, glomerular filtration rate and lipid profile before the switch and after 24 weeks of bictegravir treatment. The existence of clinical and analytical adverse effects was also determined. Results: A total of 79 patients switched to B/F/TAF from non-INI-based therapies. At 24 weeks after the switch, 96.1% in the OT analysis and 92.4% in the ITT analysis were found to have a viral load of less than 50 copies. The attached table shows analytical values referring to the primary and secondary endpoints of effectiveness and safety at baseline and week 24 and the statistical significance of the change. This meant a significant increase of 15.1% over the percentage of virologic suppression at baseline. No significant changes were detected in CD4+ lymphocyte count, glomerular filtration rate or lipid profile. The rate of adverse events was 5.1% and only 3 patients discontinued treatment due to AEs. Conclusions: The results of this study suggest that patients can switch to B/F/TAF from non-INI-based therapies without compromising the effectiveness or safety of ART. Furthermore, some patients with residual viremia may achieve virological suppression with B/F/TAF. In addition, it is a safe treatment that reduces drug-drug interactions and may improve adherence. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 1 1 2 1 2 85
RkJQdWJsaXNoZXIy Mzc2ODc=